GHRP-6: Structure, Receptor, and Research Findings

Here’s a bit of trivia that still surprises people: GHRP-6 was studied for over a decade before anyone figured out what it binds to. It’s old. Six residues, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, roughly 872 Da, and it flips on the exact receptor your own ghrelin uses. So what do the actual papers say about it? That’s what the rest of this is. We’ve linked every source, so argue with us if you want.

What GHRP-6 actually is

Chemistry first, since nobody argues about that part. GHRP-6 is a synthetic hexapeptide, sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, mass near 872 Da [3]. Notice two of the residues sit in the D configuration. That’s on purpose. D-amino acids shrug off the proteases that would otherwise shred an all-L peptide, so the thing survives in solution better than its size suggests. Class-wise it’s a growth hormone secretagogue, which is just a long way of saying it’s an agonist at GHS-R1a.

Now the weird part. When GHRP-6 first showed up, the receptor it works through hadn’t been found. GHS-R1a only got cloned in 1996, and that paper placed it in the pituitary and in the arcuate and infundibular hypothalamus of swine and humans [1]. Read that again: people spent years publishing on a peptide whose target was a blank. Worth remembering when you wade into the older papers.

A short history worth knowing

GHRP-6 grew out of a batch of synthetic peptides built to poke at GH release, and this happened well before anyone knew the receptor or the natural ligand. Peptide first, target later. Odd way round, and it left a mark on the early papers. Read the late-1980s and early-1990s work and you’ll see clear effects on GH output next to frank admissions that the binding site was anybody’s guess. The receptor showed up in 1996 [1]. The ligand, 1999 [2]. Anything on GHRP-6 from before 1996, then, was written by people flying blind on the target. That’s why some of their mechanism talk feels fuzzy. Only once both pieces landed did the tidy “it’s a GHS-R1a agonist” version come into view.

The ghrelin connection

Three years later, Kojima’s group pulled the natural ligand out of rat stomach and called it ghrelin: 28 amino acids, with an octanoyl group hanging off serine 3 [2]. That acyl group isn’t decoration. Strip it and, per the same paper, GH release stops. So GHRP-6, in short, is a small synthetic stand-in for ghrelin at GHS-R1a. Hence the pairing. Want the bigger split between the release peptides and the releasing-hormone peptides? Our GHRH versus GHRP overview walks the receptor difference.

What the pituitary studies measured

The cleanest mechanistic data come from reverse hemolytic plaque assays on dispersed rat pituitary cells. Mitani’s group ran human GHRH against GHRP-6 and found both bumped the fraction of plaque forming cells and the mean plaque area, two numbers that together track GH secretion [4]. At 100 nM, GHRP-6 drove the total secretion index well over vehicle. Put GHRH and GHRP-6 in together and output rose again, but here the authors kept their heads: the combination was additive, not synergistic, and a somatostatin analog took the edge off both [4]. Lesson: two secretagogues on one cell don’t just multiply.

Pharmacokinetics in people

For once, a research peptide with clean human PK behind it. Cabrales and colleagues measured plasma GHRP-6 in nine healthy men at 100, 200 and 400 micrograms per kilogram, tracking it with a validated LC-MS assay anchored to a carbon-13 internal standard [3]. The data fit a two compartment model, R-squared over 0.99, and even the 5 ng/mL floor was still measurable at 12 hours in everyone [3]. A fast distribution phase? Exactly what you’d guess for a small, mostly water-loving peptide. These are numbers you can cite, unlike the hand-wavy “fast acting” line that fills older write-ups.

How it’s characterized analytically

Peptide identity and purity get established the same way for GHRP-6 as for any synthetic peptide: reversed-phase HPLC for purity, mass spectrometry for identity, and the exact mass near 872 Da is the anchor point [3]. One wrinkle: aggregation. Santana’s group showed, with biophysical methods, that the hexapeptide can self-assemble into nanotube-like structures in solution [5]. Not a party fact. It changes how a sample behaves on a column and how you’d prep a reference standard. When you see a certificate of analysis, the HPLC trace and the MS confirmation are what matter.

GHRP-6 and CJC-1295

Older content loved to pair GHRP-6 with CJC-1295, so let’s be clear about what CJC-1295 actually is. It’s a GHRH analog, not a secretagogue. Its party trick: a covalent grip on endogenous albumin that drags its half-life out to around 8 days [6]. In GHRH knockout mice, once-daily CJC-1295 brought body length back to normal; stretch the schedule out and it fell short [6]. In healthy men it left GH pulsatility alone while lifting trough GH roughly 7.5-fold [7]. Different receptors, these two. Which is precisely why anyone bothered looking at them together. For the DAC versus no-DAC distinction, see our CJC-1295 comparison.

How GHRP-6 compares to related secretagogues

And GHRP-6 is hardly the only GHS-R1a agonist on the bench. Ipamorelin, introduced in 1998 as the first selective growth hormone secretagogue, earned that label because it set off GH release with far less of the off-target pituitary noise the older GHRPs carried [8]. Selectivity, basically. That’s what tips a lab toward one over the other. Weighing the pentapeptide against GHRP-6? Our Ipamorelin overview and the GHRP-2 overview dig into the receptor-level detail.

Stability and handling notes

Part of why GHRP-6 lingers in old protocols: for a small peptide, it’s fairly tough. Those two D-amino acids slow enzymatic breakdown, and that was designed in, not luck [3]. That said, it’s still a peptide: it’s sensitive to repeated freeze-thaw cycles and prolonged time in solution, and the self-assembly behavior documented by Santana and colleagues means concentration and buffer choice can change how a sample reads on an analytical column [5]. None of that is exotic, but it’s the kind of detail that gets lost in content written to fill a page rather than to inform a bench.

Comparing certificates of analysis? Two numbers carry the weight: HPLC purity and the mass-spec confirmation against that ~872 Da mark. The rest is secondary. For how that verification process works across compounds, our overview of third-party tested peptides walks through it.

Frequently asked questions

What is the sequence of GHRP-6?

His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, a six residue synthetic peptide with a molecular weight near 872 Da [3].

Does GHRP-6 bind the same receptor as ghrelin?

Yes. Both act at GHS-R1a, the receptor cloned in 1996; ghrelin is the endogenous ligand isolated in 1999 [1][2].

How is GHRP-6 purity confirmed?

Through reversed-phase HPLC for purity and mass spectrometry for identity, with the ~872 Da mass as the confirmation point [3].

References

1. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996. PMID 8688086
2. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999. PMID 10604470
3. Cabrales A, Gil J, Fernandez E, et al. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci. 2013. PMID 23099431
4. Mitani M, Kaji H, Abe H, Chihara K. Growth hormone (GH)-releasing peptide and GH releasing hormone stimulate GH release from subpopulations of somatotrophs in rats. J Neuroendocrinol. 1996. PMID 8933359
5. Santana H, Avila CL, Cabrera I, et al. How does growth hormone releasing hexapeptide self-assemble in nanotubes? Soft Matter. 2014. PMID 25325399
6. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006. PMID 16822960
7. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006. PMID 17018654
8. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID 9849822